9 IPOs priced deals this week. This brings April’s total to 20, making it the busiest month of the past 22. These 20 pricings were almost enough to double the count for the year, raising that number to 45. Five biotechs priced in April, doubling the total...read more
Verona Pharma, which is developing inhaled treatments for respiratory diseases, raised $78 million by offering 5.8 million shares at $13.50, in line with the expected price of $13.49. Verona Pharma plans to list on the Nasdaq under the symbol VRNA. Jefferies...read more
A whopping eight deals are on the calendar for the week ahead after a flurry of launches hit Monday. The month's 11 IPOs already make it the most active year-to-date, but if all eight April deals on ...read more
Verona Pharma, which is developing inhaled treatments for respiratory diseases, announced terms for its US IPO on Tuesday. The biotech currently trades on London's AIM market under the symbol VRP, and plans to list on the Nasdaq under the symbol VRNA.
The...read more
US IPO Weekly Recap: Floor & Décor pops 53%, Carvana skids 26%
9 IPOs priced deals this week. This brings April’s total to 20, making it the busiest month of the past 22. These 20 pricings were almost enough to double the count for the year, raising that number to 45. Five biotechs priced in April, doubling the total...read more
Verona Pharma prices IPO at $13.50
Verona Pharma, which is developing inhaled treatments for respiratory diseases, raised $78 million by offering 5.8 million shares at $13.50, in line with the expected price of $13.49. Verona Pharma plans to list on the Nasdaq under the symbol VRNA. Jefferies...read more
US IPO Week Ahead: Cloudera leads pack of 8 deals
A whopping eight deals are on the calendar for the week ahead after a flurry of launches hit Monday. The month's 11 IPOs already make it the most active year-to-date, but if all eight April deals on ...read more
Respiratory biotech Verona Pharma sets terms for $75 million US IPO
Verona Pharma, which is developing inhaled treatments for respiratory diseases, announced terms for its US IPO on Tuesday. The biotech currently trades on London's AIM market under the symbol VRP, and plans to list on the Nasdaq under the symbol VRNA. The...read more